Impact of Eliminating Cost-Sharing by Medicare Beneficiaries for Follow-Up Colonoscopy After a Positive Stool-Based Colorectal Cancer Screening Test.

Medicare coverage of a follow-up colonoscopy after a positive stool-based colorectal cancer (CRC) screening test with no patient cost-sharing started January 2, 2023, which may favorably affect screening behavior. This analysis estimated the clinical and economic effects of increased CRC screening participation potentially resulting from this policy change in Medicare beneficiaries. The validated CRC-AIM model simulated three guideline-endorsed CRC screening strategies for average-risk individuals (colonoscopy every 10 years, annual fecal immunochemical test, triennial multi-target stool DNA) from ages 65-75 years. The base-case scenario assumed 0% coinsurance for initial screening and follow-up colonoscopy, real-world screening test use (colonoscopy=45.3%, stool-based test=24.4%, unscreened=30.3%), and real-world follow-up colonoscopy rates. Comparative scenarios assumed an increase in the overall screening rate from 0-15% (5% increments) and an increase in the follow-up colonoscopy rate from 0-15% (5% increments). The base-case scenario resulted in 128 life-years gained (LYG)/1000 individuals versus no screening and total screening and treatment costs of $7938/person. The changes resulted in an increase of up to 26 LYG/1000 individuals and a decrease in total screening and treatment costs by as much as $128/person. Follow-up colonoscopy at $0 coinsurance became cost-saving with any increase in either overall screening or follow-up colonoscopy. Policies that remove cost barriers to completing CRC screening may increase rates of screening participation, potentially improving economic and clinical outcomes.